<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02859402</url>
  </required_header>
  <id_info>
    <org_study_id>DSMC 2016-05-051</org_study_id>
    <nct_id>NCT02859402</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas</brief_title>
  <acronym>RRTCLAlloSCT</acronym>
  <official_title>Allogeneic Stem Cell Transplantation With 3-days Busulfan Plus Fludarabine as Conditioning in Patients With Relapsed or Refractory T-, NK/T-cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Keimyung University Dongsan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role&#xD;
      of allogeneic stem cell transplantation have been demonstrated in these patients. This&#xD;
      clinical trial is studying the efficacy and safety of busulfan plus fludarabine as&#xD;
      conditioning therapy followed by allogeneic stem cell transplantation (Allo-SCT) in T- and&#xD;
      NK/T-cell lymphoma patients who have relapsed or are refractory to previous chemotherapies&#xD;
      including autologous transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Conditioning therapy&#xD;
&#xD;
        -  Busulfan (Busulfex®; Patheon Manufacturing Services LLC, Greenville, NC 27834) 3.2 mg/kg&#xD;
           + 5% DW (the diluent quantity should be 10 times the volume of Busulfan, so that the&#xD;
           final concentration of busulfan becomes approximately 0.5 mg/mL), intravenously for 3&#xD;
           hours once daily for 3 days (days -7 to -5)&#xD;
&#xD;
        -  Fludarabine (Fludarabine®, Zydus Hospira Oncology Private Ltd., Ahmedabad, India) 30&#xD;
           mg/m2 + 5% DW 100㎖, intravenously for over 1 hour once daily for 6 days (days -8 to -3)&#xD;
&#xD;
             -  Busulfan should be infused as soon as completion of fludarabine infusion&#xD;
&#xD;
      Primary objective of this study I. To determine the 2-year progression-free survival of this&#xD;
      reduced toxicity conditioning in relapsed or refractory T- and NK/T-cell non-hodgkin lymphoma&#xD;
      patients.&#xD;
&#xD;
      Secondary endpoints I. To evaluate the response rate, engraftment rate and time to&#xD;
      engraftment, 2-year overall survival, 100-days treatment-related mortality, regimen-related&#xD;
      toxicities by CTCAE version 4.03, post-transplantation complications (HVOD, acute/chronic&#xD;
      graft-versus-host disease (GVHD), cytomegalovirus (CMV) infection,CMV disease) of this&#xD;
      reduced toxicity conditioning in relapsed or refractory T- and NK/T-cell non-hodgkin lymphoma&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>2 year progression-free survival rate from the date of allogeneic stem cell transplantation. Estimated using the Kaplan-Meier method. Median value will be provided.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>3-months</time_frame>
    <description>Response will be measured after 3 months of the date of allogeneic stem cell transplantation. Mean value will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>Day 30</time_frame>
    <description>Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet engraftment</measure>
    <time_frame>Day 30</time_frame>
    <description>Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>2 year overall survival rate from the date of allogeneic stem cell transplantation. Estimated using the Kaplan-Meier method. Median value will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100-days treatment-related mortality</measure>
    <time_frame>Days 100</time_frame>
    <description>Summarized using standard descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of regimen-related toxicities</measure>
    <time_frame>Day 30</time_frame>
    <description>Toxicity according to CTCAE version 4.03. Summarized using standard descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hepatic venoocclusive disease (HVOD)</measure>
    <time_frame>Day 30</time_frame>
    <description>Summarized using standard descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute graft-versus-host disease (GVHD) grades I-IV</measure>
    <time_frame>Day 100</time_frame>
    <description>Summarized using standard descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD grades I-IV</measure>
    <time_frame>2 year</time_frame>
    <description>Summarized using standard descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cytomegalovirus (CMV) infection</measure>
    <time_frame>2 year</time_frame>
    <description>Summarized using standard descriptive statistics.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Lymphoma, Extranodal NK-T-Cell</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conditioning chemotherapy: Fludarabine and Busulfan followed by Allogeneic stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>intravenous, 3.2 mg/kg + 5% DW (the diluent quantity should be 10 times the volume of Busulfan, so that the final concentration of busulfan becomes approximately 0.5 mg/mL), once daily for 3 hours for 3 days (days -7 to -5)</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>intravenous, 30 mg/m2 + 5% DW 100㎖, over 1 hour once daily for 6 days (days -8 to -3)</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 19 - 65&#xD;
&#xD;
          2. Histologically confirmed T or NK cell lymphomas :&#xD;
&#xD;
               -  anaplastic large cell lymphoma&#xD;
&#xD;
               -  angioimmunoblastic T-cell lymphoma,&#xD;
&#xD;
               -  peripheral T-cell lymphoma, NOS&#xD;
&#xD;
               -  NK/T-cell lymphoma&#xD;
&#xD;
          3. Relapsed after or refractory to one or more of previous chemotherapy including&#xD;
             frontline autologous HSCT.&#xD;
&#xD;
          4. At least one measured lesion using conventional CT or PET CT at the time of relapse&#xD;
             after or refractory to one or more of previous chemotherapy and before salvage&#xD;
             chemotherapy&#xD;
&#xD;
          5. Complete or Partial response after short cycles of salvage chemotherapy&#xD;
&#xD;
          6. Patients who have HLA full-match (8/8 in HLA-A, B, C, DR by DNA high-resolution&#xD;
             technique) or one-locus mismatch (7/8) sibling, or unrelated bone marrow or peripheral&#xD;
             blood or cord blood stem cell donors&#xD;
&#xD;
          7. ECOG performance status ≤ 2&#xD;
&#xD;
          8. Charlson Comorbidity Index (CCI) before HSCT ≤ 3&#xD;
&#xD;
          9. Adequate renal function : serum creatinine level &lt; 2.0 mg/dL&#xD;
&#xD;
         10. Adequate liver function :&#xD;
&#xD;
               -  Transaminase (AST/ALT) &lt; 3 X upper normal value (or &lt; 5 x ULN in the presence of&#xD;
                  lymphoma involvement of the liver)&#xD;
&#xD;
               -  Total bilirubin &lt; 2 X upper normal value (or &lt; 5 x ULN in the presence of NK/T&#xD;
                  involvement of the liver)&#xD;
&#xD;
         11. Cardiac ejection fraction ≥ 50 % as measured by MUGA or 2D ECHO without clinically&#xD;
             significant abnormality&#xD;
&#xD;
         12. No clinically significant infection&#xD;
&#xD;
         13. No clinically significant bleeding symptoms or sign&#xD;
&#xD;
         14. Patients who decided to participate in this study and signed for a written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Adult T cell leukemia/lymphoma, Lymphoblastic lymphoma, Primary cutaneous CD30+ T cell&#xD;
             disorders Mycosis fungoides, Sezary SD&#xD;
&#xD;
          2. Patients who have previously performed Allo-HSCT&#xD;
&#xD;
          3. T cell lymphoma with primary central nervous system (CNS) Involvement.&#xD;
&#xD;
             ** However, patients who have only had prophylactic intrathecal or intravenous&#xD;
             chemotherapy against CNS disease are eligible.&#xD;
&#xD;
          4. Patients with a known history of HIV seropositivity or HCV (+).&#xD;
&#xD;
             ** Patients with HBV are eligible. However, primary prophylaxis using antiviral agents&#xD;
             is recommended for HBV carrier or prevent HBV reactivation during whole treatment&#xD;
             period.&#xD;
&#xD;
          5. Any other malignancies within the past 5 years&#xD;
&#xD;
             ** Except curatively treated non-melanoma skin cancer or in situ carcinoma of cervix&#xD;
             uteri&#xD;
&#xD;
          6. Ejection fraction &lt; 50% by a echocardiography&#xD;
&#xD;
          7. FEV1 &lt;60% or DLCO &lt;60% by a pulmonary function test&#xD;
&#xD;
          8. ECOG performance status 3 or 4&#xD;
&#xD;
          9. Combined serious medical problem or disease&#xD;
&#xD;
               -  Serious or unstable heart disease although proper treatment&#xD;
&#xD;
               -  Myocardial infarction in recent 3 months&#xD;
&#xD;
               -  Underlying serious neurologic or psychiatric disease including dementia or&#xD;
                  seizure&#xD;
&#xD;
               -  Active uncontrolled infection including hepatitis B and C&#xD;
&#xD;
               -  Serious other medical problems observed by the doctors in charge of the patient&#xD;
&#xD;
         10. Pregnant or lactating women, women of childbearing potential not employing adequate&#xD;
             contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Young Rok Do, MD., Ph.D.</last_name>
    <phone>+82-10-3541-1160</phone>
    <email>dyr1160@dsmc.or.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Hyun Lee, MD., Ph.D.</last_name>
    <phone>+82-10-9397-5694</phone>
    <email>hidrleejh@dau.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dong-A University</name>
      <address>
        <city>Busan</city>
        <zip>602-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Hyun Lee, MD., Ph.D.</last_name>
      <phone>+82-10-9397-5694</phone>
      <email>hidrleejh@dau.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Rok Do, MD., Ph.D.</last_name>
      <phone>+82-10-3541-1160</phone>
      <email>dyr1160@dsmc.or.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Keimyung University Dongsan Medical Center</investigator_affiliation>
    <investigator_full_name>Young Rok Do</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>T-cell Non-Hodgkin Lymphoma</keyword>
  <keyword>NK/T-cell Non-Hodgkin Lymphoma</keyword>
  <keyword>Relapsed, refractory</keyword>
  <keyword>Conditioning</keyword>
  <keyword>Allogeneic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>age,gender, disease type, stage, previous chemotherapy regimens, response to transplantation, patient survival, progression, toxicity profiles to the transpantation will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

